Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study.
Rewadee JenraumjitSurarong ChinwongDujrudee ChinwongTipaporn KanjanarachThanat KshetradatTinakon WongpakaranNahathai WongpakaranPublished in: BMC research notes (2020)
A total of 133 (80% women, mean age 78.38 years, SD 7.4) were recruited. No difference in sex, age and comorbid diseases was observed between participants who took ACs, benzodiazepines (BZDs) and AChEIs. The most common prescribed ACs was quetiapine, being used for behavioral and psychological symptoms (BPSD). Multilevel analysis showed that the change of mental state examination scores were significantly predicted in the group using ACs (t (169), - 2.52, p = .020) but not with the groups using BZD (t (162), 0.84, p = .440). Evidence showed that older adults with Alzheimer's disease and exposed to ACs exhibited lower global cognitive scores than those without AC exposure. Using ACs could be a trade-off between controlling BPSD and aggravating cognitive impairment. Highlighting the awareness of the potential anticholinergic effect is important and may be the best policy.
Keyphrases
- acute coronary syndrome
- cognitive impairment
- cognitive decline
- healthcare
- middle aged
- mental health
- public health
- community dwelling
- physical activity
- polycystic ovary syndrome
- climate change
- sleep quality
- pregnant women
- risk assessment
- human health
- pregnancy outcomes
- skeletal muscle
- mild cognitive impairment
- data analysis